NASDAQ:HEME
$0.10
(3/18 4:00PM)
| Open | $0 |
Mkt Cap | $607,000 |
| High | $0 |
52Wk High | $0.10 |
| Low | $0 |
52Wk Low | $0.10 |
| Volume | 0 |
Avg Vol 10D | 0 |
A Word Of Caution
Stocks trading for less than $1 are loosely termed "penny" stocks. Healthmed Services Limited (HEME) is selling for less than $1 per share. While we stand by our ratings methodology for long term value investors, often times "penny" stocks can be more volatile. Because many "penny" stocks are lightly traded their stock price can fluctuate because of a single large trade. Also, there is generally less analyst coverage of such "penny" stocks and thus less information from which to base our rating.
While this company may not get as much press because of its low stock price, please take a moment to look at the RazorWire feed on the right hand side of the report. Each time Healthmed Services Ltd is mentioned on business television or influential blogs recently should be displayed. This helps to bring you up to speed on any major issues they are facing right now.
Therefore, (and as always), check additional sources and available information regarding Healthmed Services Ltd before making an investment decision.
HEME Revenue
Currently, the data available for HEME is not sufficient for us to properly evaluate the stock. We will resume coverage as the data allows.
HEME Cash Earnings
Cash (and the ability of a company to generate it) is a pivotal analysis at Ockham Research. With HEME, we have found that we don't have as many years of positive Cash Earnings as we would like in order to run an analysis. When a company like HEME has had several years of negative Cash Earnings mixed in with their positive years, it can be difficult to really get a good analysis of their potential. At Ockham, we always advise that Cash is key to any investment, so investors should consider the lack of positive years available as a signal that other types of analysis may need to be more heavily relied upon in HEME's case.
HEME Dividends
When determining a company's future prospects for success, Ockham Research sees analysis of dividend payments as a key additional factor. Even though it isn't imperative for HEME to shell out a dividend in order to receive a positive rating, it can be helpful to further our analysis. As far as our investing methodology goes, it is not necessary to pay a dividend in order to get a favorable rating, so as for right now HEME gets a neutral rating for the dividend portion of the model. As you can see, we are not receiving historical dividend information from our data provider on HEME at this time.
